Introduction: Cerebral vasospasm in patients after aneurysmal subarachnoid hemorrhage (aSAH) continues to be a major source of morbidity despite significant clinical and basic science research. The removal of blood and its degradation products from the subarachnoid space through prophylactic lumbar drainage (LD) is a favorable option. However, several studies have delivered conflicting conclusions on its efficacy after aSAH.

Methods: Systematic searches of Medline, Embase, and Cochrane Central Register of Controlled Trials were performed. The primary outcome was a good functional outcome (modified Rankin scale score, 0-2). Secondary outcomes included symptomatic vasospasm, secondary cerebral infarction, and mortality.

Results: A total of 14 studies reporting on 2473 patients with aSAH were included in the meta-analysis. Compared with the non-LD group, no significant differences were found in the rates of good functional outcomes in the LD group at discharge to 1 month (risk ratio [RR], 1.28; 95% confidence interval [CI], 0.64-2.58) or at 6 months (RR, 1.12; 95% CI, 0.97-1.41). These findings were consistent in the subgroup analyses of only randomized controlled trials or observational studies. LD was associated with lower rates of symptomatic vasospasm (RR, 0.61; 95% CI, 0.48-0.77), secondary cerebral infarction (RR, 0.59; 95% CI, 0.45-0.79), and mortality at discharge to 1 month (RR, 0.58; 95% CI, 0.41-0.82). The effect on mortality diminished at 6 months (RR, 0.70; 95% CI, 0.34-1.45). However, when analyzing only randomized controlled trials, the benefit of LD on lower rates of mortality continued even at 6 months (RR, 0.75; 95% CI, 0.58-0.99).

Conclusions: For aSAH patients, the use of LD is associated with benefits in the rates of vasospasm, secondary cerebral infarctions, and mortality, without an increased risk of adverse events.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.wneu.2024.01.062DOI Listing

Publication Analysis

Top Keywords

controlled trials
12
secondary cerebral
12
lumbar drainage
8
patients aneurysmal
8
aneurysmal subarachnoid
8
subarachnoid hemorrhage
8
good functional
8
symptomatic vasospasm
8
vasospasm secondary
8
cerebral infarction
8

Similar Publications

Active Support is a support model designed to enhance quality of life through activity engagement in people with intellectual disabilities. The aim of the current study was to investigate whether implementation of Active Support affected quality of life, well-being, and activity engagement of residents with mild to moderate intellectual disabilities, using a cluster randomised controlled design. Fourteen services were recruited, and Active Support was implemented after conducting baseline assessments.

View Article and Find Full Text PDF

Background: Injectable platelet-rich fibrin (i-PRF) has the capacity to release great amounts of several growth factors, as well as to stimulate increased fibroblast migration and the expression of collagen, transforming growth factor β, and platelet-derived growth factor. Consequently, i-PRF can be used as a bioactive agent to promote periodontal tissue regeneration.

Objective: We aim to compare and evaluate the effectiveness of i-PRF in periodontal tissue regeneration.

View Article and Find Full Text PDF

Aim: Electronic cigarette use (vaping) has increased rapidly among adolescents globally. Most electronic cigarettes (e-cigarettes) contain nicotine, which is addictive and can cause behaviour problems and mood dysregulation. We sought to assess whether an educational intervention increased knowledge about vaping-related health risks and desire to quit among high school students.

View Article and Find Full Text PDF

Background: There is increasing recognition that the interpretation of active-controlled HIV prevention trials should consider the counterfactual placebo HIV incidence rate, that is, the rate that would have been observed if the trial had included a placebo control arm. The PrEPVacc HIV vaccine and pre-exposure prophylaxis trial (NCT04066881) incorporated a pre-trial registration cohort partly for this purpose. In this article, we describe our attempts to model the counterfactual placebo HIV incidence rate from the registration cohort.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!